Issue 159 • October 2025

China's CGT edge

As Western biotechs struggle with financing, China emerges as a dominant force in the CGT trial space.

Briefing

Business concerns about tariffs continue to rise

Feature

As US funding falters, mRNA cancer vaccine pioneers face new hurdles

Interview

Charles River's Steve Bulera on alternatives to animal testing

Comment

Cystic fibrosis market set to reach $16bn by 2034, in the 7MM

In association with

09/22/2025 15:11:51
  • Home | China's CGT edge
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Syngene Company Insight
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Zenatek Company Insight
  • Simtra
  • Alphial Company Insight
  • TriLink BioTechnologies
  • In Depth
  • China takes lead in CGT trials amid Western funding challenges
  • As US funding falters, mRNA cancer vaccine pioneers face new hurdles
  • Europe’s cannabis pharmaceuticals market matures amid cautious investment
  • Animal testing alternatives to dominate, but not overnight
  • One platform can bring countless gains to clinical trial financial management
  • Cystic fibrosis market forecast to reach $16.0bn by 2034 in the 7MM
  • AlfatestLAB Company Insight
  • Gerteis
  • Listings
  • Events
  • Excellence Awards
  • Buyer's Guides
  • Next issue
09/22/2025 00:00:00